Axelopran represents a new class of host-level immune restoration therapy. Unlike traditional immunotherapy combinations such as dual checkpoint inhibitors, bispecific antibodies, or cytokine agonists, which often increase toxicity and are limited to narrow biomarker-defined populations, axelopran works by removing an immune barrier created by opioid signaling. It restores T-cell infiltration and reduces tumor-promoting effects without interfering with pain control. The drug is orally administered, well-tolerated, and broadly applicable across solid tumors.